Join ASPHO's Industry Relations Council
Work with your target audience to advance pediatric hematology/oncology
As an organization that supports ASPHO’s mission and goals, your company is eligible to join ASPHO’s Industry Relations Council (IRC) to enjoy year-round benefits.
As an IRC member, you’ll gain:
- Expanded access to ASPHO leadership
- Ongoing visibility and recognition
- Exclusive discounts
- Opportunities to collaborate with ASPHO and its membership to improve patient care
Tiered participation ensures companies of all sizes benefit by joining ASPHO's IRC. Your company can join at the associate, executive, or premier level to take advantage of the benefits that best fit your needs, from newsletter advertising to 3-hour advisory board or focus group meetings.
Apply to join ASPHO's IRC today. For more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it. .
Join These Companies on ASPHO's Industry Relations Council
Platinum Level
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare
diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for more than 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. Alexion focuses research efforts on novel molecules and targets that include the complement cascade, and development efforts in hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 70 countries. To learn more, please visit www.alexion.com.
Alexion is committed to helping your patients access the care they need. OneSource™ is a free, personalized patient support program offered by Alexion. Whether your patient is newly diagnosed or has had their condition for some time, our specialists are available for patients and their caregivers. We can help them make sense of their health insurance coverage, answer questions about treatment and connect them to community resources. We’re committed to helping your patients start and stay on track with their prescribed treatment. To learn more visit www.alexiononesource.com.
Executive Level
bluebird bio
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. To learn more, visit https://www.bluebirdbio.com/.
For patients considering a bluebird bio gene therapy, there’s my bluebird support. my bluebird support is staffed by Patient Navigators who can provide resources, help answer questions, and assistance with next steps throughout the treatment journey. Available at no cost, enroll your patient online to start the conversation.
Servier
As the U.S. affiliate of the Servier Group, Servier Pharmaceuticals is focused on delivering transformative oncology and neurology medicines that fill a critical need for patients who are underserved by current therapies.
Since opening its headquarters in Boston, U.S., in 2018, Servier Pharmaceuticals quickly became a leader in cancer care and is taking bold steps to build a powerful portfolio of precision therapeutics for patients living with cancer and neurological conditions.
Governed by a non-profit foundation, Servier Group’s private corporate governance enables the company to combine its resources and global network with cutting-edge science and creativity to develop tailored solutions that drive meaningful progress for patients.
Servier is actively seeking alliances, partnerships and acquisitions across all stages of oncology and neurology research and development to accelerate the delivery of innovative treatments to patients as part of its trailblazing One Innovation Engine R&D strategy.
Servier Pharmaceuticals has been named one of the Best Places to Work by The Boston Business Journal for four consecutive years. For more information about Servier, visit Servier.us and follow Servier on LinkedIn.
Associate Level
Kedrion
Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries.
For other ways to support or partner with ASPHO, review our corporate support opportunities.